R&D

What does the past generation of failure in Alzheimer’s R&D look like in one slide?

Just how bad is it in the Alzheimer’s R&D arena?

IQVIA just put together something of an impressionist piece on the slew of trial failures recorded over the years (below).

Except for one pop in 2014 — for a dementia drug, Namzaric — there’s nothing by way of an FDA approval going back to 2002, 17 years of failure and disaster, with Eli Lilly, Pfizer, J&J and others going over the amyloid beta cliff. That’s made the big players leery of this field, but the prospect of being the only significant therapy on the market for millions of patients continues to fuel the drive toward something — anything — to throw against the disease.

Getting something reimbursable, though, won’t be easy.


Credit: IQVIA

 


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->